The glycine transporter type 1 inhibitor N-[3-(4′-fluorophenyl)-3-(4′-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior

Journal of Neuroscience

Volumn 23, Issue 20, 2003, Pages 7586-7591

  Kinney, Gene G ^a   Sur, Cyrille ^a   Burno, Maryann ^a   Mallorga, Pierre J ^a   Williams, Jacinta B ^a   Figueroa, David J ^a   Wittmann, Marion ^a   Lemaire, Wei ^a   Conn, P Jeffrey ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

c Fos; DBA 2J mouse; Glycine; Long term potentiation; NMDA; Prepulse inhibition; Schizophrenia

Indexed keywords

CARRIER PROTEIN; CLOZAPINE; GLYCINE TRANSPORTER 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N [3 (4' FLUOROPHENYL) 3 (4' PHENYLPHENOXY)PROPYL]SARCOSINE; PROTEIN C FOS; SARCOSINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUDITORY STIMULATION; BINDING SITE; BRAIN; COMPLEX FORMATION; CONTROLLED STUDY; DENTATE GYRUS; ELECTROSTIMULATION; HIPPOCAMPUS; HORMONE ACTION; IMMUNOREACTIVITY; IN VIVO STUDY; MALE; NEUROTRANSMISSION; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN TARGETING; PSYCHOSIS; RAT; RECEPTOR BINDING; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR SENSITIVITY; SENSORY NERVE; SPINAL CORD; SYNAPSE;

EID: 0041920952     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.23-20-07586.2003     Document Type: Article

References (42)

1. Abraham WC, Mason SE (1988) Effects of the NMDA receptor/channel antagonist CPP and MK801 on hippocampal field potentials and long-term potentiation in anesthetized rats. Brain Res 462:40-46.
2. Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY (1997) Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 283:226-234.
3. Atkinson BN, Bell SC, De Vivo M, Kowalski LR, Sechner SM, Ognyanov VI, Tham C-S, Tsai C, Jia J, Ashton D, Klitenick MA (2001) ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter. Mol Pharmacol 60:1414-1420.
4. Aubrey KR, Vandenberg RJ (2001) N[3-(4′-Fluorophenyl)-3-(4′-phenyl-phenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transport. Br J Pharmacol 134:1429-1436.
5. Berger AJ, Dieudonne S, Ascher P (1998) Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses. J Neurophysiol 80:3336-3340.
6. Bergeron R, Meyer TM, Coyle JT, Greene RW (1998) Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci USA 95:15730-15734.
7. Chumakov I, Blumenfeld M, Guerassimenko O, Cavarec L, Palicio M, Abderrahim H, Bougueleret L, Barry C, Tanaka H, La Rosa P, Puech A, Tahri N, Cohen-Akenine A, Delabrosse S, Lissarrague S, Picard F-P, Maurice K, Essioux L, Millasseau P, Grel P, et al. (2002) Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci USA 99:13675-13680.
8. Daly DA, Moghaddam B (1993) Actions of haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci Lett 152:61-64.
9. Danysz W, Parsons AC (1998) Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 50:597-664.
10. Davis M (1988) Apomorphine, D-amphetamine, strychnine and yohimbine do not alter prepulse inhibition of the acoustic startle reflex. Psychopharmacology (Berl) 95:151-156.
11. 2 dopamine receptor antagonists on Fos protein expression in the striatal complex and entorhinal cortex of the nonhuman primate. Synapse 23:182-191.
12. Ferraro TN, Hare TA (1985) Free and conjugated amino acids in human CSF: influence of age and sex. Brain Res 572:154-163.
13. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156:117-154.
14. Goff DC, Tsai G, Manoach DS, Coyle JT (1995) Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 152:1213-1215.
15. Hashimoto A, Oka T (1997) Free D-aspartate and D-serine in the mammalian brain and periphery. Prog Neurobiol 52:325-353.
16. Heresco-Levy U, Javitt D, Ermilov M, Mordel C, Horowitz A, Kelly D (1996) Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 169:610-617.
17. Heresco-Levy U, Javitt D, Ermilov M, Mordel C, Silipo G, Lichenstein M (1999) Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56:29-36.
18. Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC (2002) Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry 159:480-482.
19. Ishimaru M, Kurumaji A, Toru M (1992) NMDA-associated glycine binding site increases in schizophrenic brains. Biol Psychiatry 32:379-381.
20. Ishimaru M, Kurumaji A, Toru M (1994) Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis. Biol Psychiatry 35:84-95.
21. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP (1994) Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151:1234-1236.
22. Javitt DC, Sershen H, Hashim A, Lajtha A (1997) Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacology 17:202-204.
23. Javitt DC, Balla A, Sershen H, Lajtha A (1999) Reversal of phencyclidine-induced effects byglycine and glycine transport inhibitors. Biol Psychiatry 45:668-679.
24. Johnson JW, Ascher P (1987) Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325:529-531.
25. Laube B, Hirai H, Sturgess M, Betz H, Kuhse J (1997) Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit. Neuron 18:493-503.
26. Leveque JC, Macias W, Rajadhyaksha A, Carlson RR, Barczak A, Kang S, Li XM, Coyle JT, Huganir RL, Heckers S, Konradi C (2000) Intracellular modulation of NMDA receptor function by antipsychotic drugs. J Neurosci 20:4011-4020.
27. Lynch G (1998) Memory and the brain: unexpected chemistries and a new pharmacology. Neurobiol Learn Mem 70:82-100.
28. 3H]-(N-[3-(4′-fluorophenyl)-3-(4′-phenylphenoxy)propyl]) sarcosine. Neuropharmacology, in press.
29. McCaughran J, Mahjubi E, Decena E, Hitzemann R (1997) Genetics, haloperidol-induced catalepsy and haloperidol-induced changes in acoustic startle and prepulse inhibition. Psychopharmacology (Berl) 134:131-139.
30. Morris RGM, Anderson E, Lynch G, Baudry M (1986) Selective impairment of learning and blockade of LTP by NMDA receptor antagonist, AP5. Nature 319:774-776.
31. Olivier B, Leahy C, Mullen T, Paylor R, Groppi VE, Sarnyai Z, Brunner D (2001) The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics? Psychopharmacology (Berl) 156:284-290.
32. Olney JW, Newcomer JW, Farber NB (1999) NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33:523-533.
33. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates, Ed 4. San Diego: Academic.
34. Robertson GS, Fibiger HC (1992) Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46:315-328.
35. Robertson GS, Matsumura H, Fibiger HC (1994) Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271:1058-1066.
36. Smith KE, Borden LA, Hartig PR, Branchek T, Weinshank RL (1992) Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron 8:927-935.
37. Tauck DL, Ashbeck GA (1990) Glycine synergistically potentiates the enhancement of LTP induced by a sulfhydryl reducing agent. Brain Res 519:129-132.
38. Thomson AM, Walker VE, Flynn DM (1989) Glycine enhances NMDA-receptor mediated synaptic potentials in neocortical slices. Nature 338:422-424.
39. Toth E, Lajtha A (1986) Antagonism of phencyclidine-induced hyperactivity by glycine in mice. Neurochem Res 11:393-400.
40. Tsai G, Yang P, Chung L-C, Lange N, Coyle J (1998) D-Serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44:1081-1089.
41. Wan W, Ennulat DJ, Cohen BM (1995) Acute administration of typical and atypical antipsychotic drugs induces distinctive patterns of Fos expression in the rat forebrain. Brain Res 688:95-104.
42. Watanabe Y, Saito H, Abe K (1992) Effects of glycine and structurally related amino acids on generation of long-term potentiation in rat hippocampal slices. Eur J Pharmacol 223:179-184.